We are live on !
Find out more
Bender Robert & Associates Portfolio holdings
AUM
$525M
Turnover
26.53%
1-Year Est. Return
38.43%
This Fund
S&P 500
This Quarter Est. Return
+13.74%
1 Year Est. Return
+38.43%
3 Year Est. Return
+145.82%
5 Year Est. Return
+189.35%
10 Year Est. Return
+1,046.87%
AUM
$155M
AUM Growth
+$14M
(+9.9%)
Cap. Flow
-$3.62M
Cap. Flow % of AUM
Cap. Flow %
-2.33%
Top 10 Holdings %
Top 10 Hldgs %
59.77%
Holding
49
New
1
Increased
1
Reduced
47
Closed
–
Avg Time Held
3.3
years
Top 10 Avg Time Held
2.6
years
Top 20 Avg Time Held
2.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
+$212K |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$54.1K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vipshop
VIPS
|
+$418K |
| 2 |
Cognizant
CTSH
|
+$359K |
| 3 |
Apple
AAPL
|
+$343K |
| 4 |
CELG
Celgene Corp
CELG
|
+$204K |
| 5 |
Ulta Beauty
ULTA
|
+$197K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 32.99% |
| 2 | Consumer Discretionary | 26.66% |
| 3 | Technology | 23.43% |
| 4 | Communication Services | 12.51% |
| 5 | Industrials | 1.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Apple
AAPL
$5.2T
| $20.4M | 13.13% |
567,304
-10,424
| -2% | -$343K |
2013 Q2
15 quarters
|
|
|
CELG
2
DELISTED
Celgene Corp
CELG
| $10.5M | 6.78% |
84,495
-1,705
| -2% | -$204K |
2013 Q2
15 quarters
|
|
3
Intuitive Surgical
ISRG
$155B
| $10.2M | 6.6% |
120,177
-2,457
| -2% | -$194K |
2013 Q2
15 quarters
|
|
4
Illumina
ILMN
$30.9B
| $9.6M | 6.19% |
57,890
-1,139
| -2% | -$179K |
2013 Q2
15 quarters
|
|
|
5
Ulta Beauty
ULTA
$28B
| $8.57M | 5.52% |
30,054
-720
| -2% | -$197K |
2013 Q2
15 quarters
|
|
6
Meta Platforms (Facebook)
META
$1.62T
| $8M | 5.16% |
56,348
-1,060
| -2% | -$142K |
2015 Q1
8 quarters
|
|
7
Amazon
AMZN
$2.87T
| $7.64M | 4.92% |
172,320
-4,240
| -2% | -$177K |
2013 Q2
15 quarters
|
|
8
Gilead Sciences
GILD
$209B
| $6.51M | 4.2% |
95,891
-1,113
| -1% | -$78.3K |
2013 Q2
15 quarters
|
|
|
9
Cognizant
CTSH
$28.3B
| $5.78M | 3.72% |
97,088
-6,237
| -6% | -$359K |
2013 Q2
15 quarters
|
|
|
CAVM
10
DELISTED
Cavium, Inc.
CAVM
| $5.5M | 3.54% |
76,728
-1,668
| -2% | -$112K |
2013 Q2
15 quarters
|
|
|
11
Vipshop
VIPS
$6.25B
| $5.07M | 3.27% |
189,327
-33,757
| -15% | -$418K |
2014 Q1
12 quarters
|
|
12
Mercado Libre
MELI
$75.5B
| $5.01M | 3.23% |
23,704
-384
| -2% | -$75.2K |
2013 Q2
15 quarters
|
|
13
Booking.com
BKNG
$118B
| $4.87M | 3.14% |
68,425
-925
| -1% | -$61K |
2013 Q2
15 quarters
|
|
|
14
Alphabet (Google) Class C
GOOG
$3.59T
| $4.59M | 2.96% |
110,620
+1,320
| +1% | +$54.1K |
2013 Q2
15 quarters
|
|
15
lululemon athletica
LULU
$12.2B
| $4.35M | 2.8% |
83,839
-1,145
| -1% | -$75.4K |
2013 Q2
15 quarters
|
|
16
Starbucks
SBUX
$122B
| $4.23M | 2.73% |
72,477
-1,615
| -2% | -$91.4K |
2013 Q2
15 quarters
|
|
|
VMW
17
DELISTED
VMware, Inc
VMW
| $4.2M | 2.71% |
45,623
-1,033
| -2% | -$90.9K |
2013 Q2
15 quarters
|
|
|
ALXN
18
DELISTED
Alexion Pharmaceuticals
ALXN
| $3.88M | 2.5% |
32,009
-1,340
| -4% | -$173K |
2013 Q2
15 quarters
|
|
19
AbbVie
ABBV
$521B
| $3.86M | 2.49% |
59,221
-1,091
| -2% | -$68.6K |
2015 Q2
7 quarters
|
|
20
Alphabet (Google) Class A
GOOGL
$3.63T
| $3.42M | 2.2% |
80,700
-1,840
| -2% | -$77.4K |
2015 Q4
5 quarters
|
|
21
Baidu
BIDU
$26.4B
| $2.56M | 1.65% |
14,840
-380
| -2% | -$66.9K |
2013 Q2
15 quarters
|
|
22
Biogen
BIIB
$37.3B
| $2.52M | 1.63% |
9,236
-222
| -2% | -$62.8K |
2015 Q1
8 quarters
|
|
23
Protolabs
PRLB
$1.6B
| $1.65M | 1.06% |
32,317
-950
| -3% | -$50.3K |
2015 Q2
7 quarters
|
|
24
Kinder Morgan
KMI
$71.2B
| $979K | 0.63% |
45,012
-1,701
| -4% | -$37.2K |
2013 Q3
14 quarters
|
|
25
Home Depot
HD
$348B
| $866K | 0.56% |
5,900
-410
| -6% | -$58.1K |
2013 Q2
15 quarters
|
|
Similar funds
H2CM
Bender Robert & Associates's Q1 2017 Portfolio in Review
As of Q1 2017, Bender Robert & Associates held 49 positions worth $155M, up 9.9% from $141M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Trading was light in Q1 2017: portfolio turnover was 2%. Bender Robert & Associates opened 1 new position and made no exits, leaving the 49-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 33% a quarter earlier, followed by Consumer Discretionary and Technology.
- Bender Robert & Associates's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 4,311 shares worth $235K.
- Bender Robert & Associates added most to Alphabet (Google) Class C in Q1 2017, an estimated $54.1K increase.
- Bender Robert & Associates's biggest Q1 2017 reduction was Vipshop, cutting an estimated $418K.
- Bender Robert & Associates's ten largest holdings make up 60% of its $155M portfolio in Q1 2017.
- Bender Robert & Associates opened 1 new position and closed 0 in Q1 2017.
- Bender Robert & Associates's portfolio value rose 9.9% quarter-over-quarter to $155M.
Based on Bender Robert & Associates's 13F filing for Q1 2017, filed 12 May 2017.